Ligand id: 9510

Name: andecaliximab

No information available.
Summary of Clinical Use
Andecaliximab (GS-5745) is being evaluated in various clinical trials (max Phase 3) for cancers and inflammatory conditions. Click here to link to all of the trials registered with Trials in ulcerative colitis and Crohn's disease were terminated early (2016) due to meeting pre-specified futility and efficacy criteria in an interim analysis of unblinded efficacy and safety data. A Phase 2 study in rheumatoid arthritis has also been terminated. Evaluation for anti-cancer efficacy appears to be ongoing. Phase 2 trial NCT02864381 is evaluating andecaliximab in combination with the anti-PD-1 checkpoint inhibitor nivolumab in unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.